论文部分内容阅读
目的:探讨紫杉醇联合铂类方案对中晚期宫颈癌的临床疗效。方法:98例中晚期宫颈癌患者平均分为两组,观察组采用紫杉醇联合铂类方案治疗,对照组采用伊立替康联合铂类方案治疗。分别用电化学发光法、微粒子酶免疫分析法检测血清中人细胞角蛋白21-1片段(CYFRA21-1)、人鳞状细胞癌相关抗原(SCC-Ag)含量,对比两种治疗方案的临床疗效、生存质量、副反应。结果:观察组有效率73.5%显著高于对照组42.9%(P<0.01)。治疗后两组血清CYFRA21-1、SCC-Ag较治疗前均有明显降低(均P<0.05),且观察组较对照组降低更明显(P<0.05)。治疗后,两组躯体功能(PF)、情绪功能(EF)、社会功能(SF)、疲乏(FA)、食欲减退(AP)、疼痛(PA)方面均改善,其中,除EF外,观察组改善均优于对照组(均P<0.05)。观察组副反应总发生率显著低于对照组(P<0.05)。结论:紫杉醇联合铂类方案对中晚期宫颈癌疗效显著,具有改善患者生存质量、减少副反应、降低血清CYFRA21-1、SCC-Ag水平的优点。
Objective: To investigate the clinical efficacy of paclitaxel combined with platinum regimen in the treatment of advanced cervical cancer. Methods: A total of 98 patients with advanced cervical cancer were divided into two groups. The observation group was treated with paclitaxel combined with platinum regimen. The control group was treated with irinotecan plus platinum regimen. The levels of human cytokeratin 21-1 (CYFRA21-1) and human squamous cell carcinoma associated antigen (SCC-Ag) in serum were detected by electrochemiluminescence and microparticle enzyme immunoassay, respectively. The clinical efficacy of the two treatment regimens was compared Efficacy, quality of life, side effects. Results: The effective rate in observation group was 73.5%, significantly higher than that in control group (42.9%, P <0.01). Serum levels of CYFRA21-1 and SCC-Ag in both groups were significantly lower than those before treatment (all P <0.05), and the levels of serum CYFRA21-1 and SCC-Ag in the observation group were significantly lower than those in the control group (P <0.05). After treatment, the body function (PF), emotional function (EF), social function (SF), fatigue (FA), loss of appetite (AP) and pain (PA) were improved in both groups. Improve better than the control group (all P <0.05). The incidence of adverse reactions in observation group was significantly lower than that in control group (P <0.05). Conclusion: Paclitaxel combined with platinum regimen has a significant effect on advanced cervical cancer. It has the advantages of improving patients’ quality of life, reducing side effects and lowering serum levels of CYFRA21-1 and SCC-Ag.